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a b s t r a c t
Background: Low-dose rate brachytherapy is a well established treatment modality of oral
cancer. Data about high-dose rate (HDR) brachytherapy are still sparse with various frac-
tionation schedules and heterogeneous results.
Aim: The aim of our retrospective study was to evaluate the results of HDR brachytherapy
with doses of 3Gy twice daily.
Patients and methods: Twenty patients with squamous cell tongue cancer were treated in the
years 2001–2009 by exclusive HDR BT 18×3Gy twice daily. The plastic tube technique was
used. Median follow up was 47 months (7.8–118) since brachytherapy.
Results: The local and locoregional control was 85% and 68%, respectively. Bone necrosis
developed in one case treated without mandibular shielding and soft tissue necrosis in 2cases.
Conclusion: It can be concluded that HDR brachytherapy with 18×3Gy twice daily is safe
with promising local control. The risk of nodal recurrences is substantial.
© 2011 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.
Czech Republic and other countries. HDR BT has a higher. Background
rachytherapy (BT) is a well established treatment method of
arly stages of tongue cancer. BT is as effective as surgery for
umor control with better functional and cosmetic results in
majority of cases. In comparison with external beam radio-
herapy (EBRT), brachytherapy allows delivery of higher doses
f radiation in shorter time with reduction of volume of irra-
iated healthy tissues. The tumor control is improved and
ostradiation xerostomia and soft tissue ﬁbrosis are less fre-
uent.
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Most experience with BT in tongue cancer was achieved
with the manual afterloading technique and iridium wires
with continuous low-dose rate (LDR) irradiation. Continu-
ous LDR BT favors normal tissue repair during irradiation
and results in a beneﬁcial therapeutic ratio between tumor
control probability and normal tissue complication probabil-
ity. High-dose rate (HDR) afterloading devices have replaced
LDR brachytherapy in many radiotherapy departments in the
1biological effect in comparison with LDR BT, which is more
profound for normal late reacting tissues than for tumor.
The consequence is a less beneﬁcial therapeutic ratio. HDR
. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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implants must be fractionated and numerous small fractions
are recommended to allow for repair of healthy tissues and to
achieve biological equivalence to LDR brachytherapy.2
For the use of HDR BT in oral cancer, only some contro-
versial results of limited values are available to date3 with
various fractionation schemes. HDR is often considered to be
dangerous for interstitial implants because of higher risk of
complications. In our institution, we started with HDR BT of
oral cancer in 2001 and since then we have treated 45 patients
with BT alone or in combination with EBRT.
2. Aim
The aim of our retrospective study was to evaluate the tumor
control and complications of HDR BT alone with 3Gy dose
per fraction twice daily administered to patients with tongue
cancer after tumor excision.
3. Patients and methods
3.1. Patients
Twenty patients with histologically proven squamous cell
tongue cancer were treated by HDR BT alone at the Depart-
ment of Oncology and Radiotherapy, University Hospital in
Hradec Králové between 2001 and 2010. Nine patients were
male and 11 were female, the median age was 59 years
(43–74). All patients underwent clinical examination, neck
ultrasound and chest X-ray prior to the start of the treatment.
The patients’ characteristics are presented in Table 1. All of
them were cN0cM0. Median follow up was 47 months (7.8–118)
since BT. The follow up consisted of clinical examination and
ultrasound of the neck performed at 3-month intervals, with
Table 1 – Patients characteristics.
Patients no. T category Grade Margins
inﬁl
1 1 2 R0
2 1 1 R0
3 2 2 R1
4 1 2 R1
5 1 1 R0
6 1 2 R1
7 1 2 R2
8 2 3 R1
9 1 1 R1
10 1 2 R1
11 1 2 R1
12 1 2 R1
13 1 3 R1
14 1 2 R1
15 2 2 R0
16 1 2 R1
17 1 2 R1
18 1 3 R0
19 2 2 R0
20 1 1 R1
R0=microscopically negative; R1=microscopically positive; R2=macroscoiotherapy 1 6 ( 2 0 1 1 ) 243–247
X-ray examination once per year. All the patients signed an
informed consent for the treatment.
3.2. Treatment
The surgery was limited to tumor excision. The margins were
histologically negative in 6 patients, microscopically positive
in 13 patients and macroscopically positive in 1 patient. Neck
dissection as a part of primary treatment was performed in 5
patients. The indications were lymphangioinvasion in 1 case
and tumor ulceration in 4 cases.
3.3. The brachytherapy technique
The technique involving interstitial plastic tubes with 1 cm
spacing and double-planar conﬁguration was used for the
brachytherapy. Median number of catheters was 7 (3–10). The
distribution of catheters in the central plane was either in
equilateral triangles or in squares. The afterloading catheters
were inserted through hollow stainless steel needles. Because
of the technical difﬁculties with the insertion of the plastic
tubes in the posterior part of the tongue, we invented a mod-
iﬁcation of the outer plastic tube technique. After a puncture
with a hollow needle we pushed a guiding wire through the
needle, took the needle away and, with the help of the wire,
inserted a semirigid plastic tube with a sharp end. It was pos-
sible to insert the thin part of the afterloading catheter to
the outer tube very easily, then to remove the tube and to
pull the catheter out (Fig. 1). In our experience we have never
succeeded to use the loop technique in combination with
Gammamed, because we were not able to make the source
go through the loop. Therefore, we replaced the loop tech-
nique with catheters protruding above the tongue (Fig. 2). To
ensure that the top dwell position was above the tongue sur-
face, plastic buttons of 9mm in thickness were placed at the
Depth of
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tFig. 1 – Technique of afterloading catheters insertion.
op end of the catheter. By using a longer dwell time for the
op dwell position, the tongue surface received an adequate
ose. Catheters were secured by plastic buttons. Dose distri-
utionwas calculated using the Abacus-GammaMed planning
ystem (Gammmed; Germany) in the ﬁrst 6 applications till
004; in the rest of the patients the Brachyvision (Varian;
SA) planning system and CT based planning was used, with
uch a better chance to optimize the dose to the mandible
Fig. 3), which was contoured as an organ at risk. The pre-
cription points were set at 5mm outside the catheters. All
atients received 18 fractions of 3Gy administered twice daily
ith intervals of at least 6h between fractions. The maximum
ose limit to the mandible should be <2Gy/1 cm3 without lead
hielding.
Individualized mandibular lead shielding was used in all
atients except for the ﬁrst one..4. Statistical analysis
he Kaplan–Meier survival analysis was used for the estima-
ion of survival functions.
Fig. 2 – Implantation of afterloading catheters.Fig. 3 – CT based planning of dose distribution.
4. Results
Median volume of minimum target dose (MTD) was 14.4 cm3
(2.4–44). Median mean central dose (MCD) was 4.6Gy (3.5–6.4).
Median V150 was 6.4 cm3 (1.2–18). Median dose homogeneity
index (HI =MTD/MCD) was 65% (52–87).
The estimated 5-year local control was 85% and locore-
gional control was 68%. The probability of 5-year overall
survival was 75%.
Two patients recurred only locally. One died of tumor pro-
gression to the ﬂoor of the mouth despite salvage surgery.
The other one had invasive epidermoid cancer in the region
of severe dysplasia up to carcinoma in situ. He refused sal-
vage treatment and is alive with the tumor 38 months from
the brachytherapy and 12 months from the recurrence. One
patient recurred both locally and in the regional lymphatic
nodes, and nodal recurrence only was observed in 3 patients.
All of them were treated with surgery and EBRT but died of
disease progression. The localization of nodal recurrence was
submandibular region in all cases.
Most patients experienced grade 2 acutemucositis (accord-
ing RTOG/EORTC criteria) after brachytherapy, which resolved
within 8 weeks after the treatment completion. Only the
ﬁrst patient irradiated without mandibular shielding suffered
mandibular osteoradionecrosis which was cured by seque-
strotomy. In 2 patients a soft tissue radionecrosis occurred and
was resolved after conservative treatment, in one of them the
necrosis followed after a dental intervention.5. Discussion
A 5-year local recurrence-free rate for early tongue cancer
obtained by surgery is reported at 81–85% for T1 and at 77–85%
d rad
r
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for T2 tumors.4,5 The results achieved by LDR RT are compa-
rable to those of Mazeron et al. who reported a 5-year local
control rate of 87% in155patientswithT1–T2N0M0oral tongue
carcinoma.6 Published data reporting the use of HDR BT in the
treatment of patients with oral cancer are still sparse. Addi-
tionally, those series vary in fractionation schemes, doses and
results.
Umeda et al. compared the results in 25 patients with stage
I–II tongue cancer treatedwithHDRBTwith a groupof patients
treated with traditional LDR brachytherapy.7 An average dose
of 59Gy (6Gy×9–10 fractions/5 days) was administered. Nine
(36%) of the 25 patients in theHDRgroupmanifestedwith local
recurrence. Mandibular osteonecrosis was found in 5 patients.
The local control and the incidence of osteonecrosis were sig-
niﬁcantly higher in the HDR group than in the LDR group.
Lau et al. reported only 53% local control rate in patients
treated with HDR BT. They treated patients with a total dose
of 45.5Gy in 7 fractions.8 Inoue et al. reported on Phase III
trial comparing 25 eligible patients treated with LDR BT and 25
patients treated with HDR BT for early mobile tongue cancer.9
Hyperfractionated HDR BT with a total dose of 60Gy in 10 frac-
tions during 1 week was used. Five-year local control rates
for the LDR and HDR groups were 84% and 87%, respectively.
Tongue ulcer occurred in 1 patient in both groups. Bone expo-
sure occurred in 2 patients in the HDR group. For 1 of the 2
patients with bone exposure, the spacer reducing the dose of
mandible was not used.
Yamazaki et al. examined the comparability of LDR BT with
HDR BT in patients with early oral tongue carcinoma.10 HDR
BT was used in 58 patients to the total dose of 48–60Gy in
8–10 fractions. The 5-year local control was 84%, which was
comparable with the LDR group.
In our department, we used smaller doses per fraction in
comparison with previous studies, which is recommended
also by the American Society for Brachytherapy.11 Accord-
ing to the linear quadratic model, 18 times 3Gy in 14 days
is equivalent to the dose of 66.77Gy to the tumor with dose
rate of 0.5Gy/h in 7 days, with a slightly higher effect on
late tissues (extrapolated response rate 114Gy vs. 108Gy).
Parameters used for the calculation were: ˛/ˇ ratio = 10Gy
for tumor and 3Gy for late tissues; sublethal damage repair
time constant 1.2h−1 for tumor and 0.46h−1 for late tissues;
repopulation parameter 0.3 day−1 for tumor and 0.01day−1
for late tissues. Stepping iridium source of Gammamed HDR
device and computerized treatment planning allow for opti-
mized dose distribution inside the brachytherapy implant and
present physical advantage of HDR brachytherapy. Our regime
is close to the fractionation published recently by Guinot
et al.12 Guinot’s study of 50 patients with oral tongue car-
cinoma treated by HDR brachytherapy includes 17 patients
treated by exclusive BT with doses of 3–4Gy per fraction b.i.d.
with a minimum interval of 6h between fractions. The local
control was 100%, no case of bone necrosis was reported for
this group of patients and soft tissue necrosis was observed
in 4 patients. Our results show also a low risk of late compli-
cations and a high probability of local control achieved with
small doses per fraction administered twice daily.We observed regional recurrences in 4 of 20 patients
(20%) with clinically negative (N0) neck nodes, in 1 case
regional metastasis was combined with local recurrence. Alliotherapy 1 6 ( 2 0 1 1 ) 243–247
the patients died of the disease despite salvage surgery and
EBRT. A wait-and-see policy is often recommended for the
majority of patients with early tongue cancers treated by
BT,13–15 because a routine policy of elective neck dissection
for clinically negative lymph nodes would subject a signif-
icant proportion of patients to an unnecessary procedure.16
The incidence of regional metastasis of N0 early tongue can-
cer is reported to be about 20–50%.17,18 In the study of Fujita
et al., 36 of 127 (28%) patients with T1-2N0 oral tongue tumors
treated by BT alone had regional metastases and 58% patients
were salvaged by neck dissection.15 Inoue et al. described
6 nodal metastases both in a group of 26 patients treated
by LDR BT and a group of 25 patients treated by HDR BT
(23% and 24%, respectively).9 In a large study of Nakagawa,19
neck metastases occurred in 185 (39%) of the 476 patients
who underwent brachytherapy alone and their incidence of
neck metastases was not signiﬁcantly different from the inci-
dence in the group irradiated by combination of EBRT with BT.
Macroscopic appearance of the tumor was the only signiﬁcant
risk factor for nodal recurrence identiﬁed by a multivariate
analysis. The incidence of cervical lymph node metastases
was 62% among the invasive/ulcerative type of the tongue
carcinoma and was lower among the superﬁcial type and exo-
phytic/nodular type (20 and 35%, respectively). In our study 3
of 4 patients with neck recurrence presented with the ulcera-
tive type of tumorwith tumor thickness≥10mm. In the recent
study of Chakrabarti et al.,20 the authors recommend prophy-
lactic nodal irradiation in addition to brachytherapy even for
early stage oral cancers treatedwith interstitial brachytherapy.
Tumor thickness>6mm and the need for multiplanar implant
were found to be statistically signiﬁcant risk factors for nodal
recurrence. A new promising approach to select patients for
immediate neck treatment is to predict lymphatic metastases
based on gene expression proﬁle analysis.21
6. Conclusion
The HDR BT schedule of 18×3Gy twice daily is effective, has
low risk of late complications and can be escalated. The risk
of nodal recurrences is substantial. Mandibular shielding is
necessary to reduce the risk of osteonecrosis.
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